Summary

Description

Summary

The main purpose of this study is to assess clemastine as a remyelinating agent in patients with acute optic neuritis.The study will also evaluate the tolerability of clemastine, originally approved as first-generation antihistamine, in patients with optic neuritis. Study procedures will include assessments for evidence of remyelination in the anterior visual pathway and in the brain using electrophysiologic techniques and magnetic resonance imaging. If they are on one, patients in this study can remain on their standard disease modifying treatment during the course of the study. However, patients cannot participate in any other investigational new drug research study concurrently.

Official Title

A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis

Keywords

Optic Neuritismultiple sclerosiseye painvision lossNeuritisClemastine

Eligibility

You can join if…

Open to people ages 18–55

Patients diagnosed or suspected to have an acute demyelinating optic neuritis in at least one eye within 2 weeks from the onset of any visual symptom other than pain